Rebuilding Big Pharma ’ s Business Model
نویسنده
چکیده
Four inter-related building blocks can provide the new foundation: focusing R&D efforts and commercial capabilities; making use of product and capability partnerships; providing customer solutions (not just “therapeutics”), and creating a business unit based organization model instead of a functional one. Companies need to find a combination of these building blocks that makes best use of their strengths, improves returns and manages risk.
منابع مشابه
BRIC Health Systems and Big Pharma: A Challenge for Health Policy and Management
BRIC nations – Brazil, Russia, India, and China – represent 40% of the world’s population, including a growing aging population and middle class with an increasing prevalence of chronic disease. Their healthcare systems increasingly rely on prescription drugs, but they differ from most other healthcare systems because healthcare expenditures in BRIC nations have exhibited the highest revenue gr...
متن کاملThe moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance
In the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters' patent expirations, this paper examines the moderating role of firms' absorptive capacity in external innovation activities of Big Pharma firms. The study indicates a rising interest of Big Pharma in acquisitions of and alliances with biotechnology companies. Unfortunately, this increased interest is not...
متن کاملThe Role of Psychological Traits in Market Mavensim Using Big Five Model
Personality research has approached a salient consensus step due to widespread use of individual differences, converging on five big model factors with marketing concept. This paper clarifies a market mavenism psychology concept and relates market mavens with big five factor model. Market Mavens are consumer which have tendency to become especially involved in the marketplace. The purpose of th...
متن کاملAn Idealized Design For A Networked Change Approach In A Pharmaceutical R&D Organization
Big Pharma is confronted with an unsustainable business model. This is characterized by high attrition rates for medicines under development, increasing regulatory thresholds, and technical complexity of treating diseases of unmet medical need (e.g. Alzheimer’s ). This has driven up the cost of drug development. Pharma companies are using various approaches to stimulate innovation while also ac...
متن کاملThe paradigm shift to an “open” model in drug development
The rising cost of healthcare, the rising cost for drug development, the patent cliff for Big pharma, shorter patent protection, decrease reimbursement, and the recession have made it more difficult for the pharmaceutical and biotechnology industry to develop drugs. Due to the unsustainable amount of time and money in developing a drug that will have a significant return on investment (ROI) it ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2003